Drug intelligence / Profile preview

PepElk

Development stage: Unknown
Lead developer: Melkin Pharmaceuticals
Modality: Small Molecules, Peptides
Administration: Systemic

Overview

PepElk is a synthetic peptide-based small molecule drug developed by Melkin Pharmaceuticals. It is designed to selectively interfere with substrates downstream of the ERK signaling pathway, without globally inhibiting the entire cascade. This targeted approach aims to reduce off-target toxicity and side effects commonly associated with classical ERK inhibitors. PepElk has shown promising preclinical activity in central nervous system disorders, specifically depression and drug abuse, by modulating specific cellular responses involved in these pathologies[1][4][6].

Targets

Mitogen-activated protein kinase 1/3 (ERK1/2)–ETS domain-containing protein Elk-1 protein-protein interface

Beyond the preview

Go deeper on PepElk.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on PepElk.

Explore the full profile